XTL Biopharmaceuticals Ltd. (XTLB): $XTLB Chart from #DDAmanda

$XTLB Chart from #DDAmanda - #1

Zardiw · 2024-03-21T00:53:56.5770000Z

$XTLB Chart from #DDAmanda - #1 Stock Screener : Scans are preset. Push a Button. Find Winners Early: https://ddamanda.com/Charts/DDAmandaXTLB.jpg Z

Play Episode

5min

Proactive - Interviews for investors

Cuscal FY25 update: profit grows on stable volumes

Cuscal Limited Managing Director Craig Kennedy talked with Proactive at AIM's Small and MIdcap conference about the company’s role in Australia's financial infrastructure and its recent financial performance for the first half of FY25. Kennedy explained that Cuscal is one of only five organisations in Australia with the full suite of licensing, infrastructure, and capabilities required to offer end-to-end payment services—alongside the four major banks. The company serves a range of clients including other banks, corporates, and fintechs, as well as working with NAB’s UBank division. Kennedy emphasised Cuscal’s position as a “neutral, independent” access point to payment infrastructure. On financial performance, Kennedy said Cuscal expects to “modestly exceed the forecast in the prospectus” issued at the time of its IPO in November. He noted that the business enjoys stable, predictable revenue and has completed significant investment in areas like real-time payments and operational upgrades. As a result, the company is beginning to see operational leverage. Kennedy stated: “Mid to high single digit volume growth will translate to low double digit profit growth.” He said H1 FY25 results showed 7% volume growth and between 12% to 13% profit growth. Reflecting on sector innovation, Kennedy described Cuscal as an "airport" enabling new players—like fintechs—to create and deliver new customer experiences on top of a stable infrastructure. He also said investors view the company as a “safe harbour,” appreciating its unique market position and stable growth outlook. #Cuscal #ASXStocks #FintechAustralia #PaymentsInfrastructure #CraigKennedy #InvestorUpdates #RealTimePayments #ASXConference #FinancialServices #BankingInnovation

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Proactive - Interviews for investors

Saunders expands defense & fuel infrastructure work

Saunders International Ltd Managing Director and CEO Mark Benson talked with Proactive at the AIM's Small and Midcap Conference about the company’s strong momentum, recent project wins and the strategic expansion into defense and infrastructure sectors. Benson highlighted Saunders’ transformation from a tank constructor to a multi-disciplined, end-to-end engineering and construction provider. “We’ve diversified and become a multi-disciplined business… Now some of the projects we can do end-to-end,” he said, referencing the company’s work on the **Western Sydney Airport**, where it completed all elements from fuel tank construction to apron pipeline delivery. He also noted Saunders’ acquisition strategy as a driver of growth, enabling delivery of complex infrastructure through internal capabilities. Notable acquisitions include piping, civil infrastructure, and automation companies, helping the company expand its offering and grow organically and through M&A. Benson discussed the company’s extensive work in the defense sector, including the **Larrakeyah Defense Precinct** in Darwin, where Saunders handled the complete marine diesel infrastructure — from delivery to ship fueling — a capability he said sets the company apart. “Typically it’s done through 3 to 6 contractors. Now we can do that end to end.” The company now sees a $2.3 billion pipeline of directly addressable opportunities, with up to $4.8 billion in total defense-related fuel infrastructure upgrades anticipated across the next decade. Saunders is actively tendering for $580 million of that. Benson said Saunders’ unique value in defense projects includes not just technical delivery but risk reduction for government clients. “In defense, it’s not all about price. Sometimes price evaluation is only 30%. It’s about de-risking the project for the Commonwealth.” Visit Proactive’s YouTube channel for more company interviews, and don’t forget to like the video, subscribe to the channel, and turn on notific

Proactive - Interviews for investors

Opioid-Free pain relief: AFT’s global expansion strategy

AFT Pharmaceuticals Ltd Managing Director Dr Hartley Atkinson talked with Proactive at the AIM's Small and Midcap Conference about the company's unique approach to drug development, its expanding global footprint, and what lies ahead in 2025. AFT Pharmaceuticals is focused on creating pharmaceuticals "with a difference," targeting unmet needs and reducing reliance on opioids. “We don’t sell anything we don’t believe in,” said Dr Atkinson, highlighting the importance of alternatives to opioid treatments. One of the company’s key analgesic products helps avoid opioid use — a particularly timely innovation in light of the global opioid crisis. Dr Atkinson discussed the company’s core markets, with a strong presence in New Zealand and Australia, generating approximately 150 million in revenue. AFT also maintains operations in Asia and now exports to around 80 countries. The company has experienced sustained growth, having quadrupled in size over the past decade and doubled in the last five years. AFT has established six new affiliates across regions including Singapore, Hong Kong, South Africa, Canada, the UK, and Europe. Looking ahead, the company plans several product launches across Australia and New Zealand and anticipates five drug launches in China — the world’s second-largest pharmaceutical market. “For us, that’s going to be an interesting journey,” Atkinson added. #AFTPharmaceuticals #OpioidAlternatives #PharmaceuticalInnovation #ChinaPharma #DrugDevelopment #HealthcareGrowth #ASXStocks #BiotechInvesting #GlobalHealthcare #PharmaExpansion

Followers	2521
Posts	114076
Boards Moderated	27
Alias Born	01/09/2001

Volume:	1,789
Day Range:	1.17 - 1.27
Bid:	1.17
Ask:	1.27
Last Trade Time:	11:15:23 AM EDT
Total Trades:	55

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

XTLB Detailed Quote

Recent XTLB News

More XTLB News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent XTLB News

Go Ad-Free